R. F. Lafferty Initiates Coverage on Horizon Pharma (HZNP)
Research analysts at R. F. Lafferty began coverage on shares of Horizon Pharma (NASDAQ:HZNP) in a report released on Thursday, American Banking News reports. The firm set a “buy” rating and a $6.00 price target on the stock. R. F. Lafferty’s price target would indicate a potential upside of 79.64% from the stock’s previous close.
Shares of Horizon Pharma (NASDAQ:HZNP) traded down 2.69% on Thursday, hitting $3.25. 161,375 shares of the company’s stock traded hands. Horizon Pharma has a 52 week low of $1.97 and a 52 week high of $3.55. The stock’s 50-day moving average is $2.7 and its 200-day moving average is $2.53. The company’s market cap is $209.6 million.
Horizon Pharma (NASDAQ:HZNP) last released its earnings data on Friday, August 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.08. The company had revenue of $17.64 million for the quarter, compared to the consensus estimate of $16.09 million. On average, analysts predict that Horizon Pharma will post $-1.10 earnings per share for the current fiscal year.
Horizon Pharma, Inc operates as a biopharmaceutical company. It is focused on developing and commercializing medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.